Manufacturing

EMD Millipore and PharmaCell have entered into a collaboration to develop optimized large-scale expansion and harvest of HepaRG cells using bioreactor technology.

FDA receives adverse event reports related to calcium gluconate infusions.

A proposed new guideline provides a global policy for limiting metal impurities qualitatively and quantitatively in drug products and ingredients.

Uwe Gottschalk, vice-president of purification technologies, Sartorius Stedim Biotech, discusses specific challenges in protein purification.

Advances in techniques and single-use systems are revolutionizing vaccine manufacturing.

The author discusses HTST pasteurization and UHT sterilization.

Choosing the right disposable components for your application.

The report highlights a need for greater third party certification to ensure GMP vigilance.

Vetter has ready-to-submit documentation for this service in Common Technical Document (CTD) formats for the US, Europe and Japan.

The facility, which includes state-of-the-art formulation, analytical and synthetic laboratories as well as a customer training center, will focus on bioavailability enhancement and oral dosage formulations.

Fourth-generation biologics, with improved delivery and pharmacokinetics, will continue to drive an overall biologics industry that is already worth over $120 billion.

Seattle Genetics could potentially receive approximately $500 million in fees, milestones and royalties.

Industry experts discuss the implementation of QbD and PAT tools in biopharmaceutical manufacturing.

Increased manufacturer outsourcing requires clear policies and written agreements with CMOs.

The EMA's Committee for Medicinal Products for Human Use has recommended granting of marketing authorizations for the first two monoclonal antibody biosimilars.

A Q&A with SCHOTT Pharmaceutical Systems and West Pharmaceutical Services

Bills to regulate drug compounding and establish a national track and trace system face political and policy differences.

An integrated focus on product design, development, operation, and control.

Quality control for disposable-bags

Maintaining flexibility in biopharmaceutical manufacturing can deliver positive results.

Rita Peters, Editorial Director for Pharmaceutical Technology and BioPharm Inernational talks with Mani Krishnan, director of systems at EMD Millipore live at Interphex 2013 about single-use technology. In this interview they discuss areas of growth in single-use technology as well as reservations that some companies have to switching to single-use systems Krishnan identifies a few technology advances that are overcoming these objections as well as decision-making strategies for facilities considering a switch to a single-use system.

Editorial Director Rita Peters interviews Alan Fisher of Dycem about risk management is applied to contamination control for pharmaceutical manufacturing

Project will optimize expansion and harvest of human cells in bioreactors.

New Center for Pharmaceutical Advancement and Training increases number of experts and available tools in Sub-Saharan countries.

While there are those who want combination products to be controlled by a centralized pharmaceutical-type approval system, the majority of the medical technology industry wants to retain a decentralized device-focused approach.

The author discusses issues related to the supply of soft parts in the biopharma industry.

BioPharm International spoke with INTERPHEX 2013 conference-session presenters to gain insight on trends in facility and process design.

Additional challenges to the new cleanroom paradigm from concurrent multiproduct manufacturing of bulk drug substances in a controlled non-classified (CNC) ballroom environment.

BioOutsource, a contract testing services provider to the biopharmaceutical industry, has opened a new facility in Cambridge, Massachusetts. The facility marks the company's first North American offices, which were opened in response to increasing demand for the company's bioanalytical and biosafety services, particularly in the field of biologic and biosimilar characterisation.

Third compounding pharmacy recalls products due to FDA inspection.